University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Zinc status alters Alzheimer's disease progression through NLRP3-dependent inflammation

Simple item page
dc.contributor.authorRivers-Auty, Jack
dc.contributor.authorTapia, Victor S
dc.contributor.authorWhite, Claire S
dc.contributor.authorDaniels, Michael Jd
dc.contributor.authorDrinkall, Samuel
dc.contributor.authorKennedy, Paul T
dc.contributor.authorSpence, Harry G
dc.contributor.authorYu, Shi
dc.contributor.authorGreen, Jack P
dc.contributor.authorHoyle, Christopher
dc.contributor.authorCook, James
dc.contributor.authorBradley, Amy
dc.contributor.authorMather, Alison E
dc.contributor.authorPeters, Ruth
dc.contributor.authorTzeng, Te-Chen
dc.contributor.authorGordon, Margaret J
dc.contributor.authorBeattie, John H
dc.contributor.authorBrough, David
dc.contributor.authorLawrence, Catherine B
dc.contributor.institutionUniversity of Aberdeen.Rowett Instituteen
dc.date.accessioned2021-04-26T21:43:01Z
dc.date.available2021-04-26T21:43:01Z
dc.date.issued2021-03-31
dc.descriptionData collection and sharing for this project were funded by ADNI National Institutes of Health Grant U01 AG024904 and ADNI Department of Defense Award W81XWH-12-2-0012. ADNI is supported by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Company, Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. A.E.M. is a Food Standards Agency Fellow and is supported by the Biotechnology and Biological Sciences Research Council Institute Strategic Program Microbes in the Food Chain BB/R012504/1 and its constituent projects BBS/E/F/000PR10348 (Theme 1, Epidemiology and Evolution of Pathogens in the Food Chain) and BBS/E/F/000PR10351 (Theme 3, Microbial Communities in the Food Chain). J.R.-A. was a Future Leader Fellow supported by the Biotechnology and Biological Sciences Research Council fellowship grant (Understanding how dietary zinc and inflammation impact healthy ageing in the brain; BB/P01061X/1). This work was also supported by Alzheimer Society Project Grant AS-PG-2013-007 to C.B.L. and D.B. that funded the salary of J.R.-A. The Histology Facility equipment that was used in this study was purchased by the University of Manchester Strategic Fund. We thank the University of Manchester Biological Services Facility and their expert animal husbandry, the Bioimaging Facility, and the Histology Facility for making this work possible.en
dc.description.statusPeer revieweden
dc.format.extent14
dc.format.extent3874762
dc.identifier190634429
dc.identifierd5d19a9f-8b9b-4194-a4e8-89f14f022151
dc.identifier33597269
dc.identifier85103630529
dc.identifier.citationRivers-Auty, J, Tapia, V S, White, C S, Daniels, M J, Drinkall, S, Kennedy, P T, Spence, H G, Yu, S, Green, J P, Hoyle, C, Cook, J, Bradley, A, Mather, A E, Peters, R, Tzeng, T-C, Gordon, M J, Beattie, J H, Brough, D & Lawrence, C B 2021, 'Zinc status alters Alzheimer's disease progression through NLRP3-dependent inflammation', Journal of Neuroscience, vol. 41, no. 13, pp. 3025-3038. https://doi.org/10.1523/JNEUROSCI.1980-20.2020en
dc.identifier.doi10.1523/JNEUROSCI.1980-20.2020
dc.identifier.iss13en
dc.identifier.issn0270-6474
dc.identifier.urihttps://hdl.handle.net/2164/16322
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85103630529&partnerID=8YFLogxKen
dc.identifier.vol41en
dc.language.isoeng
dc.relation.ispartofJournal of Neuroscienceen
dc.subjectAPP/PS1en
dc.subjectAlzheimer's diseaseen
dc.subjectInflammationen
dc.subjectMicrogliaen
dc.subjectNLRP3en
dc.subjectZincen
dc.subjectR Medicineen
dc.subjectGeneral Neuroscienceen
dc.subjectBiotechnology and Biological Sciences Research Council (BBSRC)en
dc.subjectBB/R012504/1en
dc.subjectBBS/E/F/000PR10348en
dc.subjectBBS/E/F/000PR10351en
dc.subjectBB/P01061X/1en
dc.subjectAlzheimers Research UKen
dc.subjectAS-PG-2013-007en
dc.subject.lccRen
dc.titleZinc status alters Alzheimer's disease progression through NLRP3-dependent inflammationen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Rivers_etal_zinc_status_alters_VOR.pdf
Size:
3.7 MB
Format:
Adobe Portable Document Format
Download

Collections

All research